Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
LQWD Technologies Lightning Network Infrastructure Surpasses 1 Million Global Transactions (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Lisata Therapeutics Inc LSTA

Healthcare Biotechnology
Lisata Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company is engaged in the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other major diseases. Its lead investigational product candidate, LSTA1, is designed to activate a novel uptake pathway that allows co-administered or tethered anti-cancer drugs to... see more

Recent & Breaking News (NDAQ:LSTA)

Lisata Therapeutics to Report First Quarter 2024 Financial Results and Provide a Business Update on Thursday, May 9, 2024

GlobeNewswire May 2, 2024

Lisata Therapeutics and Qilu Pharmaceutical Announce First Patient Treated in Qilu's Phase 2 Trial in China of LSTA1 in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewswire April 23, 2024

Lisata Therapeutics Announces U.S. FDA Orphan Drug Designation Granted to LSTA1 for the Treatment of Osteosarcoma

GlobeNewswire April 9, 2024

Lisata Therapeutics to Participate in Upcoming April 2024 Industry and Investor Events

GlobeNewswire April 3, 2024

Lisata Therapeutics Announces U.S. FDA Rare Pediatric Disease Designation Granted to LSTA1 for the Treatment of Osteosarcoma

GlobeNewswire March 21, 2024

Lisata Therapeutics Reports Full Year 2023 Financial Results and Provides Business Update

GlobeNewswire February 29, 2024

Lisata Therapeutics to Host Year-End 2023 Conference Call on Thursday, February 29, 2024 at 4:30 p.m. Eastern Time

GlobeNewswire February 22, 2024

Lisata Therapeutics to Present at BIO CEO & Investor Conference

GlobeNewswire February 20, 2024

Lisata Therapeutics to Present at the Sequire Investor Summit in Puerto Rico

GlobeNewswire January 18, 2024

Lisata Therapeutics Announces First Patient Treated in the Phase 2a Trial of LSTA1 in Patients with Glioblastoma Multiforme

GlobeNewswire January 17, 2024

Lisata Therapeutics Announces Publication of Case Report on a Complete Response in a Metastatic Gastroesophageal Adenocarcinoma Patient Treated with LSTA1 in Combination with Standard-of-Care Therapy

GlobeNewswire January 4, 2024

Lisata Therapeutics Announces Completion of Enrollment in Phase 2b ASCEND Trial of LSTA1 in Metastatic Pancreatic Ductal Adenocarcinoma

GlobeNewswire December 12, 2023

Lisata Therapeutics to Present at NobleCon19 Investor Conference

GlobeNewswire November 28, 2023

Lisata Therapeutics Announces Participation in Upcoming Conferences in November

GlobeNewswire November 9, 2023

Lisata Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update

GlobeNewswire November 2, 2023

Lisata Therapeutics to Host Third Quarter 2023 Financial Results Conference Call on Thursday, November 2nd at 4:30 p.m. Eastern Time

GlobeNewswire October 26, 2023

Lisata Therapeutics Announces First Patient Treated in the Cholangiocarcinoma Cohort of the BOLSTER Trial of LSTA1, a Novel Tumor-Targeting and Penetrating Peptide

GlobeNewswire October 24, 2023

Lisata Therapeutics Announces European Medicines Agency Has Granted LSTA1 Orphan Drug Designation for the Treatment of Pancreatic Cancer 

GlobeNewswire October 17, 2023

Lisata Therapeutics Announces Participation in Upcoming Conferences in October

GlobeNewswire September 28, 2023

Lisata Therapeutics Announces Participation in InfoSec World 2023

GlobeNewswire September 20, 2023